UCB dedicates Georgia campus as UCB stock sits 29.15 percent below its high

Published on 10/15/2026 at 10:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The Georgia campus covers 460,000 square feet and 79 acres. UCB stock costs EUR 205.10 on October 15, 2026, below its EUR 289.50 high.

Georgia investment and product growth

UCB dedicated its Georgia campus site on October 9, 2026, in a project valued at USD 2.00 billion.
BIMZELX sales reached EUR 1.52 billion in the first half of 2026, while UCB reported EUR 4.27 billion in revenue.
UCB stock trades at EUR 205.10 at 10:10 a.m. CEST at Lang & Schwarz on October 15, 2026.
UCB's pipeline includes topline results scheduled for the fourth quarter of 2026.

Trading-Floor mit großen Bildschirmen, die Euronext Brussels und BEL 20 Kursverläufe zeigen — UCB S.A. (BE0003739530) im Börsen-Editorial: Trading-Floor mit Euronext Brussels und BEL 20 Kursanzeigen, Illustration mit AI erstellt.

UCB (ISIN BE0003739530) was trading at EUR 205.10 at Lang & Schwarz on October 15, 2026, at 10:10 a.m. CEST, 29.15 percent below its EUR 289.50 52-week high. The company dedicated the future site of its first U.S. biologics manufacturing campus in Georgia on October 9, 2026, according to WV News.

Georgia campus adds capacity

The planned campus represents a USD 2.00 billion investment and is expected to create 330 permanent jobs, while more than 1,000 construction jobs are projected. The facility will cover 460,000 square feet on 79 acres and is designed to support production of biologic medicines.

The project gives UCB a larger U.S. manufacturing footprint, but the financial case still rests on commercial execution. UCB generated EUR 7.70 billion in revenue in fiscal year 2025, according to the company release carried by WV News.

What drives the growth case?

BIMZELX remains the clearest quantified driver. Sales reached EUR 1.52 billion in the first half of 2026, while UCB's total revenue rose 22.00 percent to EUR 4.27 billion in that period, according to Quartr. The same update said EBITDA increased 68.00 percent, strengthening the operating backdrop for the expansion.

Three dated company milestones

On October 9, 2026, UCB dedicated the Georgia site with a USD 2.00 billion investment; on October 5, 2026, its investor update highlighted EUR 4.27 billion in first-half revenue; and on March 11, 2026, UCB's investor materials highlighted new BIMZELX clinical evidence, according to UCB.

Upcoming clinical dates

UCB's pipeline lists topline results for STACCATO alprazolam in the fourth quarter of 2026 and for several bimekizumab programs in the first half of 2027, according to UCB. Those milestones matter because the Georgia investment is intended to support both recently approved and future biologic medicines.

Stock remains below its high

The price is 29.15 percent below the EUR 289.50 52-week high, while the company's market capitalization was EUR 39.0 billion as of October 15, 2026. UCB is listed on Euronext Brussels under ticker UCB and operates in biotechnology, with neurology and immunology as its core therapeutic areas.

UCB was trading at EUR 205.10 at Lang & Schwarz on October 15, 2026, at 10:10 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of UCB stock.